anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The main objective of volume expansion is to increase stroke volume. Franck-Starling curve is schematically divided into two portions: a vertical portion which mean that an increase in preload secondary to volume expansion will induce an increase in stroke volume; and a flat portion which mean that a same increase in preload will not induce an increase in stroke volume. Perioperative optimization is based on stroke volume maximization using volume expansion. Despite national and international recommendations, stroke volume monitoring is clearly not widely adopted. This is mostly due to the cost and the invasiveness of the devices allowing stroke volume monitoring. End tidal carbon dioxide is monitored in all patients undergoing general anaesthesia and is totally non-invasive. Several studies evaluated the relationship between stroke volume and end tidal carbon dioxide and other studies evaluated the ability of changes in end tidal carbon dioxide to assess changes in stroke volume induced by volume expansion with discordant results. These studies included small sample size and were heterogeneous (intensive care unit and nor operating room, volume expansion or passive leg raising, crystalloid or colloid, 500ml and not 250 ml ....). Nowadays, it is not clear if changes in end tidal carbon dioxide can be considered as a surrogate of changes in stroke volume during a volume expansion in operating room patients. Thus, the aim of the present study is to determine if change in End Tidal Carbon Dioxide can assess the stroke volume effects of a volume expansion of 250ml of crystalloid in the operating room.

The follow up will be restricted to the duration of volume expansion. The last data will be collected just after the end of volume expansion.
BACKGROUND: The establishment of microbial communities in neonatal mammals plays a pivotal role in shaping their immune responses to infections and other immune-related conditions. This process is influenced by a combination of endogenous and exogenous factors. Previously, we reported that depletion of CD71 + erythroid cells (CECs) results in an inflammatory response to microbial communities in newborn mice.
RESULTS: Here, we systemically tested this hypothesis and observed that the small intestinal lamina propria of neonatal mice had the highest frequency of CECs during the early days of life. This high abundance of CECs was attributed to erythropoiesis niches within the small intestinal tissues. Notably, the removal of CECs from the intestinal tissues by the anti-CD71 antibody disrupted immune homeostasis. This disruption was evident by alteration in the expression of antimicrobial peptides (AMPs), toll-like receptors (TLRs), inflammatory cytokines/chemokines, and resulting in microbial dysbiosis. Intriguingly, these alterations in microbial communities persisted when tested 5 weeks post-treatment, with a more notable effect observed in female mice. This illustrates a sex-dependent association between CECs and neonatal microbiome modulation. Moreover, we extended our studies on pregnant mice, observing that modulating CECs substantially alters the frequency and diversity of their microbial communities. Finally, we found a significantly lower proportion of CECs in the cord blood of pre-term human newborns, suggesting a potential role in dysregulated immune responses to microbial communities in the gut.
CONCLUSIONS: Our findings provide novel insights into pivotal role of CECs in immune homeostasis and swift adaptation of microbial communities in newborns. Despite the complexity of the cellular biology of the gut, our findings shed light on the previously unappreciated role of CECs in the dialogue between the microbiota and immune system. These findings have significant implications for human health. Video Abstract.
The initial dose of Abstral is always 100 mcg with the only exception being patients already using Actiq. 

  1. For patients being converted from Actiq, prescribers must use the Initial Dosing Recommendations for Patients on Actiq. See Table 1 for initial dosing recommendations. Patients must be instructed to stop the use of Actiq and dispose of any remaining units.
  2. For patients converting from Actiq doses of 200 mcg and 400 mcg, initiate titration with 100 mcg and 200 mcg of Abstral, respectively and proceed using multiples of this strength. 
  3. For patients converting from Actiq doses of 600 and 800 mcg, initiate titration with 200 mcg and 200 mcg Abstral, respectively and proceed using multiples of this strength. 
  4. For patients converting from Actiq doses of 1200 and 1600 mcg, initiate titration with 200 mcg and 400 mcg Abstral, respectively and proceed using multiples of this strength.
PURPOSE:To enable the measurement of a trace prostaglandin (PGI2) derivative in a biological sample at a high sensitivity, by immobilizing an antibody to the PGI2 derivative expressed by a specified formula. CONSTITUTION:An IgG fraction as antibody is immobilized on an immuno plate, particle, test tube or the like as solid phase. The antibody is immobilized easily on the solid phase in a physical adsorption. In the use thereof, the solid phase is washed and a sample containing a PGI2 derivative (A) expressed by a formula and a reference PGI2 derivative (A) are added thereto to carry on an antigen-antibody reaction. Subsequently, an enzyme labelled PGI2 derivative is added to cause a emulating reaction with the PGI2 derivative previously added. After the end of the emulating reaction, the solid phase is washed thoroughly and an enzyme substrate is added to carry on an enzyme reaction. After a fixed reaction time, changes in the absorbance due to the decomposition of the substrate are measured spectroscopically. As a color formation occurs in response to the amount of enzyme bonded to the antibody, the amount of the PGI2 derivative is determined from the value of the absorbance. An assay is done by measuring the amount of the PGI2 derivative in the sample from a calibration curve using the reference PGI2 derivative.
DILAUDID Oral Solution or DILAUDID Tablets may cause severe hypotension including orthostatic hypotension and syncope in ambulatory patients. There is increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (e.g. phenothiazines or general anesthetics) [see Drug Interactions (7)]. Regularly evaluate these patients for signs of hypotension after initiating or titrating the dosage of DILAUDID Oral Solution or DILAUDID Tablets. In patients with circulatory shock, DILAUDID may cause vasodilation that can further reduce cardiac output and blood pressure. Avoid the use of DILAUDID Oral Solution or DILAUDID Tablets in patients with circulatory shock.
A myofascial trigger point will be assessed in the trapezius muscle and massage applied to this area of the neck. Participants in this arm will receive a negative expectation instructional set followed by a moderately painful massage (pain = 50/100). Massage will be applied for one minute, four times with assessment of pressure pain threshold at the foot between each interval.
This arm consisted from 20 males and 20 females. Placebo, with the same appearance and taste, was orally supplemented at dose of 500 mg per day for 3 months (end of November 2018- end of February 2019).
Mesenchymal stem/stromal cells (MSCs) act as a factor in tumor recurrence after drug treatment with their involvement observed in various cancer types. As a constituent of the tumor microenvironment (TME), MSCs not only provide support to tumor growth but also establish connections with diverse cell populations within the TME, serving as mediators linking different tumor-associated components. MSCs play an important role in maintaining tumor progression due to their stem cell properties and remarkable differentiation capacity. Given the intensification of tumor research and the encouraging results achieved in recent years,the aim of this article is to investigate the supportive role of MSCs in tumor cells as well as in various cellular and non-cellular components of the tumor microenvironment. Furthermore, the article shows that MSCs do not have a specific anatomical ecological niche and describes the contribution of MSCs to the maintenance of tumor homeostasis on the basis of homing, plasticity and tumor-forming properties. By elucidating the critical roles of different components of TME, this study provides a comprehensive understanding of tumor therapy and may offer new insights into defeating cancer.
Vertical and horizontal ridge augmentation will be performed using d-PTFE mesh. The graft material is autograft mixed with a xenograft in a 1:1 ratio.
Patients who will be included in this study will be treated by using he anteriorly based palatal rotational flap to close the oroantral fistula. Two paralleling incisions will be performed on the palatal side of the fistula. The distance between the two incisions will be 2 to 3 mm greater than the width of the fistula. Then the two incisions will be connected together via a circular incision at the bony end of the hard palate. The flap reflection will be performed, and the greater palatine vessels will be legated and cauterized to allow lateral repositioning of the flap over the fistula. The flap will be sutured to the buccal tissues.
In this study, LY2127399 will be tested as a potential treatment to reduce the blood proteins in some participants with ESRD. These proteins are called alloantibodies and are made by the body to react with other proteins on cells of transplanted organs called human leukocyte antigen (HLA) proteins. When a participant has these antibodies, they are referred to as HLA-presensitized. Often the presence of these antibodies, categorized by a method called the panel reactive antibody (PRA), can make a person ineligible to receive a transplant or experience very long wait times on the kidney transplant waiting list. Therefore the need to reduce the antibodies is significant for the successful treatment of ESRD. This study will treat ESRD participants for 6 months with LY2127399 and measure PRA levels for a total of 18 months.
Damage to the cerebellum produces characteristic deficits in movement coordination, known as "ataxia." Reaching movements become curved, tremulous, and over- or undershoot targets, thus affecting nearly all activities of daily living. Sitting and standing balance becomes unsteady, and walking has a characteristic 'drunken' appearance with lateral veering and a widening of the base of support. People with many types of neurological diseases (e.g. autosomal dominant ataxias (e.g. SCAs), multiple sclerosis, cerebral palsy, stroke, Freidreich's ataxia) often have disabling ataxia.

In past work the investigators have shown that many individuals with ataxia from cerebellar disease can learn simple visuomotor tasks using reinforcement learning paradigms. The investigators do not know if individuals with ataxia from cerebellar disease can improve more complex motor patterns. In general, there are few rehabilitation studies on ataxia, with most focusing on balance and walking. Yet, arm ataxia is a significant problem that affects most all activities of daily living (e.g. eating, cooking, bathing, dressing, working). Many studies have assessed reaching ataxia on single days in order to try to better understand the fundamental basis for ataxic arm movements. Based on previous literary searches, there are only a couple of small studies that have tested whether training over weeks can mitigate arm ataxia. Each of these was a case series of either 3 or 4 people, and all patients had ataxia from lesions that included structures outside of the cerebellum. Both showed some positive effects but responses varied across patients. This work that the investigators propose will look at the affects of a longer training regimen of upper limb reaching in people with cerebellar ataxia.

The investigators will study cerebellar patients that have shown the ability to learn from previous work. Subjects with cerebellar ataxia will be randomized into two groups to receive either reinforcement training or standard practice training over a 12 week period. Subjects will train for 45 minutes a day, 3 times per week for two weeks for each type of training, with a two week 'rest' period in between. After training, subjects will be asked to return for two visits to test for retention. On each training day, reinforcement training (or standard practice) will be done using an Oculus Rift and Touch 3D headset. Training encompasses reaching to a 3D target with either online visual feedback or binary feedback 400 times. Motion tracking sensors will be placed on the shoulder, elbow, wrist, and finger, in order to track movement data in real time. These studies will provide important new information about upper limb long term training with visual feedback in individuals with Cerebellar Ataxia
The invention discloses a drying method of gastrodia elata pieces and belongs to the technical field of primary processing of medicinal plants. The method includes the steps of: steam-cooking fresh gastrodia elata which has been washed before, peeling the cooked gastrodia elata, cooling the gastrodia elata, cutting the gastrodia elata into pieces, smearing a drying agent onto the gastrodia elata pieces, wrapping the gastrodia elata pieces in food-grade paper to shape the gastrodia elata, and drying the gastrodia elata. Compared with a conventional method which dries a whole plant of the gastrodia elata, the method reduces drying time by 3-5 days. The dried gastrodia elata still have the shape before drying, thereby avoiding adulteration of low-grade gastrodia elata, so that the method greatly improves anti-fake capability and the gastrodia elata pieces are convenient to use. With the drying method, the gastrodia elata pieces are increased in content of gastrodin than that in a method of drying the whole plant of the gastrodia elata by more than 23% at least. Compared with a method of drying the gastrodia elata and then cutting the gastrodia elata into pieces, the method also effectively reduces cutting loss rate and has strong capability of assembling the gastrodia elata pieces into the whole plant of the gastrodia elata.
In this group the final occlusal correction will be performed with the patient in supine position using 20 um thick articulating paper and articulating foil 8 um thick. The patient will be asked to tap 3 times on the articulating paper and occlusal correction will be done using carbide laboratory bur and rubber cone till uniform contact on all teeth is achieved in centric relation which is illustrated on the splint by a series of uniformly appearing articulating paper dots. Then the patient will be asked to make protrusive and right and left excursions to ensure smooth anterior guidance and posterior disocclusion.
Prodn. of a stable homogeneous mixt. of a finely divided active substance (I) and an at least 50-fold amt. of a coarser carrier (II) is effected by mixing (I) with a volatile solvent and a substance (II) which adheres to (I) and has an equiv. spherical dia. of 2.5 microns or less; drying the mixt. while kneading it; and mixing the prod. with (II).
Many patients with heart failure suffer from chronotropic incompetence, an inability to raise their heart rate in response to metabolic demand. Previous studies have shown that brief increases in pacing rates in patients with biventricular pacemakers can improve cardiac contractility. We hypothesize that the benefits of an increased biventricular pacing rate could be sustained and would improve cardiovascular and neurohormonal parameters in patients suffering from volume overload. We intend to prospectively evaluate this hypothesis in a single blind randomized cross-over design trial.

We will screen 40 patients who have previously implanted biventricular pacemakers (or a narrow QRS) and an elevated B-type Natriuretic Peptide (BNP) level. Following enrollment, patients will be randomly assigned to have their atrial pacing rate increased to 85 beats per minute or to be unchanged during the first of 2 visits. Patients will be unaware of their treatment assignment. They will be observed for six hours in a monitored setting. The primary outcome will be cardiac output, as measured noninvasively by NICOM (Cheetah Medical Inc., Israel) system before and after the observation period. Secondary outcomes will include changes in neurohormonal measures and thoracic impedance. If this proof-of-concept study demonstrates a positive effect, future research would evaluate the ability of increased pacing rates to prevent or abort decompensation of Congestive Heart Failure (CHF).
NEW MATERIAL:A compound expressed by formula I [two R<1> groups are same and lower alkyl; Y is a-CH=CH-CH=N-b, a-CH=CH-N=CH-b, a-N=CH- N(COR<2>)-b, etc.; a and b are binding position to the benzene ring; R<2> is lower alkyl] and/or salt thereof. EXAMPLE:5,8-Diacetoxyquinoline. USE:A remedy for wounds and delayed type allergy having promoting action on granuloma formation and inhibitory action on auricular edema. PREPARATION:A quinone expressed by formula II is reduced with a reducing agent, such as sodium hydrosulfite, to provide hydroquinone, which is then subjected to acylation reaction to afford the aimed compound expressed by formula I. Combination of an acid anhydride with a basic or acidic catalyst or an acid halide with a base is used as the acylating agent.
Patient will receive an immune lead-in of 2 cycles of Brentuximab vedotin and Nivolumab (A-O) (cycles 1 and 2), which has an appropriate futility rules in place to close early if efficacy targets are not met. At cycle 3 and 4, patients will receive A-O with R-CHP. Patients who will have achieved complete response (CR) at PET/CT before cycle 5 will receive 2 more cycles of A-O-R-CHP (cycle 5 and 6) and A-O only for cycle 7 and 8. If these patients still present CR at PET/CT after cycle 8, they will have completed therapy and will be followed up. In case of stable disease or progressive disease at PET/CT after cycle 4, the patient will be taken off the trial. Patients who present further response but no CR, at PET/CT before cycle 5 will receive 4 more cycles A-O-R-CHP (cycles 5-8). If they reach CR at PET/CT after cycle 8, they will have completed therapy and will be followed up. All patients will receive a total of 8 cycles of A-O. The cycle duration is 21 days.
When Fluorouracil Cream is applied to a lesion, a response occurs with the following sequence: erythema, usually followed by vesiculation, desquamation, erosion and reepithelialization.

Fluorouracil Cream should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil Cream is applied with the fingers, the hands should be washed immediately afterward.

Actinic or Solar Keratosis: Apply cream twice daily in an amount sufficient to cover the lesions. Medication should be continued until the inflammatory response reaches the erosion stage, at which time use of the drug should be terminated. The usual duration of therapy is from 2 to 4 weeks. Complete healing of the lesions may not be evident for 1 to 2 months following cessation of Fluorouracil Cream therapy.

Superficial Basal Cell Carcinomas: Only the 5% strength is recommended. Apply cream twice daily in an amount sufficient to cover the lesions. Treatment should be continued for at least 3 to 6 weeks. Therapy may be required for as long as 10 to 12 weeks before the lesions are obliterated. As in any neoplastic condition, the patient should be followed for a reasonable period of time to determine if a cure has been obtained.
A product containing vitamins B and G is obtained by extracting seed or grain germ material one or more times with an organic solvent, preferably at an elevated temperature, and evaporating the extract to dryness, preferably under reduced pressure.  Seed and grain materials specified are wheat, corn, rye, oats, barley, beans and peas. Solvents specified are alcohols such as methyl alcohol, ethyl alcohol, e.g. 50 per cent ethyl alcohol, butyl alcohol, and propyl alcohol; and esters such as ethyl and methyl acetate and propionate, and propyl, butyl and amyl acetates; and mixtures thereof.  The products may be mixed with food materials, e.g. malt, baked goods, beverages, sweetmeats, fruits, &c.  Reference has been directed by the Comptroller to Specifications 103,294, [Class 2 (iii)], and 366,516.ALSO:A product containing vitamins B and G, which may be mixed with food materials, e.g. malt, baked goods, beverages, sweetmeats, fruits, &c., is obtained by extracting seed or grain germ material one or more times with an organic solvent, preferably at an elevated temperature, and evaporating the extract to dryness, preferably under reduced pressure.  Seed and grain materials specified are wheat, corn, rye, oats, barley, beans and peas. Solvents specified are alcohols such as methyl alcohol, ethyl alcohol, e.g. 50 per cent ethyl alcohol, butyl alcohol, and propyl alcohol; and esters such as ethyl and methyl acetate and propionate, and propyl, butyl and amyl acetates; and mixtures thereof.  Reference has been directed by the Comptroller to Specifications 103,294, [Class 2 (iii)], and 366,516.
Provided are a tandem epitope polypeptide vaccine for novel coronavirus and use thereof. Specifically, a vaccine polypeptide for novel coronavirus pneumonia is provided on the basis of analysis and study of the RBD sequence and structural information of the S protein of SARS-CoV-2. Said vaccine polypeptide comprises the following elements connected in series: a generic Th epitope sequence, a B cell epitope sequence and a T cell epitope sequence. The B cell epitope and the T cell epitope have an amino acid sequence from the RBM region of the S protein of SARS-CoV-2. Provided are a vaccine composition containing said vaccine polypeptide and use thereof. Experiments show that the vaccine polypeptide of the present invention can enable cynomolgus monkeys to initiate strong cellular and humoral immunity and to generate neutralizing antibodies that block the binding of RBD and ACE2, and can be used for preventing and treating novel coronavirus pneumonia.
This protocol randomizes persons soon-to-be-released from a large urban jail to treatment with extended-release naltrexone (XR-NTX), a full opioid antagonist that prevents the activity of heroin and other opioids. Investigators at NYUSOM and NYC DOHMH will recruit heroin dependent persons from NYC jails who are soon-to-be-released, not accessing opioid agonist pharmacotherapy, with lowered tolerance due to incarceration, and extremely likely to relapse and risk accidental overdose at release. All N=40 participants receive a two-session, individual psychosocial intervention, Motivational Interviewing. Half (n=20) will be randomized to pre-release treatment with XR-NTX. Immediately and one month following release, participants will be offered continued psychosocial and medication-assisted treatment (naltrexone, buprenorphine, or methadone) at Bellevue Hospital, including a second XR-NTX dose among XR-NTX arm participants. The primary outcome is relapse to sustained opioid use during the first 30 days post-release. We hypothesize an XR-NTX arm will report significantly lower rates of sustained opioid relapse following release.